A study by Barbier et al. aimed to propose actionable recommendations that can facilitate the use of biosimilars both on a clinical and practical level. The authors report results based on the insights from 44 expert interviews with healthcare professionals (physicians, hospital pharmacists, nurses), patient(s) (representatives) and regulators across Europe [1].

The study outlines the considerations of various stakeholders on how to implement biosimilar switching and design incentives to stimulate biosimilar use and translates them into practical, overarching and strategic recommendations.

Initially, there was strong desire for the adoption of a structured and collaborative approach to implement a switch. Detailed proposals are given in the paper on how this can be approached and communicated to the patient. To further increase trust in the use of biosimilars in clinical practice, it was deemed valuable to disseminate evidence from and experience with (multiple) switching to healthcare providers and provide them with clear, one-voice regulatory guidance about the interchangeability of biosimilars and their reference products. Further, it was believed important to apply a pragmatic approach when taking switch decisions; and to avoid mandated switching. Allowing stakeholder communication and alignment when implementing biosimilars was deemed to be an essential factor of a successful implementation strategy.

Several approaches to improve stakeholder motivation to use biosimilars emerged from the interviews. Generally, incentives to offset the effort of healthcare professionals associated with a switch were believed necessary. Incentive schemes should be tailored to the level of effort required and could involve a combination of non-financial and financial incentives. Non-financial incentives include, for example, transparent reporting about biosimilar-related savings and their allocation. In terms of tangible incentives, gainsharing agreements emerged as the preferred way to reward stakeholders, as savings could partially serve to optimize local clinical care.

The results and recommendations outlined in this study may support healthcare professionals and policymakers when planning to improve the use of biosimilars in healthcare systems.

Conflict of interest
Several of the authors of the research paper [1] reported conflict of interest, including being involved in consulting, advisory work and speaking engagements, stakeholder roundtables, participating in advisory board meetings and contributing to studies on biologicals and biosimilars for pharmaceutical companies.

For full details of the authors’ conflict of interest, see the research paper [1].

Abstracted by Liese Barbier, PhD Researcher, Regulatory Evaluation and Market Access Biosimilars, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium.

GaBI Journal Citation Impact
1.7 – CiteScore 2019 (calculated on 6 May 2020)
2.0 – CiteScoreTracker 2020 (Last updated on 7 February 2021)

Submit a manuscript to GaBI Journal

Related articles
Sustainable biosimilar policies in Europe

International policies for interchangeability, switching and substitution of biosimilars

Reference
1. Barbier L, Simoens S, Vulto AG, et al. European stakeholder learnings regarding biosimilars: Part II—improving biosimilar use in clinical practice. BioDrugs 2020;34(6):797-808.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.